Back to Search
Start Over
Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Jun 30; Vol. 12, pp. 666991. Date of Electronic Publication: 2021 Jun 30 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- The HIV-1 viral inhibition assay (VIA) measures CD8 T cell-mediated inhibition of HIV replication in CD4 T cells and is increasingly used for clinical testing of HIV vaccines and immunotherapies. The VIA has multiple sources of variability arising from in vitro HIV infection and co-culture of two T cell populations. Here, we describe multiple modifications to a 7-day VIA protocol, the most impactful being the introduction of independent replicate cultures for both HIV infected-CD4 (HIV-CD4) and HIV-CD4:CD8 T cell cultures. Virus inhibition was quantified using a ratio of weighted averages of p24+ cells in replicate cultures and the corresponding 95% confidence interval. An Excel template is provided to facilitate calculations. Virus inhibition was higher in people living with HIV suppressed on antiretroviral therapy (n=14, mean: 40.0%, median: 43.8%, range: 8.2 to 73.3%; p < 0.0001, two-tailed, exact Mann-Whitney test) compared to HIV-seronegative donors (n = 21, mean: -13.7%, median: -14.4%, range: -49.9 to 20.9%) and was stable over time (n = 6, mean %COV 9.4%, range 0.9 to 17.3%). Cross-sectional data were used to define 8% inhibition as the threshold to confidently detect specific CD8 T cell activity and determine the minimum number of culture replicates and p24+ cells needed to have 90% statistical power to detect this threshold. Last, we note that, in HIV seronegative donors, the addition of CD8 T cells to HIV infected CD4 T cells consistently increased HIV replication, though the level of increase varied markedly between donors. This co-culture effect may contribute to the weak correlations observed between CD8 T cell VIA and other measures of HIV-specific CD8 T cell function.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Xu, Weideman, Abad-Fernandez, Mollan, Kallon, Samir, Warren, Clutton, Roan, Adimora, Archin, Kuruc, Gay, Hudgens and Goonetilleke.)
- Subjects :
- Antiviral Agents therapeutic use
CD4-Positive T-Lymphocytes immunology
Case-Control Studies
Cells, Cultured
Coculture Techniques
Cross-Sectional Studies
HIV Core Protein p24 immunology
HIV Seropositivity blood
HIV Seropositivity drug therapy
HIV Seropositivity virology
Humans
Treatment Outcome
CD8-Positive T-Lymphocytes immunology
HIV Seropositivity immunology
HIV-1 immunology
Host Microbial Interactions immunology
Virus Replication immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 34276657
- Full Text :
- https://doi.org/10.3389/fimmu.2021.666991